| 20th Jul 2022 2:33 pm |
RNS |
Holding(s) in Company |
| 20th Jul 2022 7:00 am |
RNS |
NEW STUDY OF PARSORTIX SYSTEM IN NSCLC |
| 19th Jul 2022 10:00 am |
RNS |
Director/PDMR Shareholding |
| 15th Jul 2022 7:00 am |
RNS |
Results of Capital Raise |
| 14th Jul 2022 5:24 pm |
RNS |
Retail Offer via PrimaryBid |
| 14th Jul 2022 5:23 pm |
RNS |
Proposed Placing and Retail Offer |
| 8th Jul 2022 5:30 pm |
RNS |
Issue of Equity |
| 29th Jun 2022 4:35 pm |
RNS |
Result of 2022 Annual General Meeting |
| 27th Jun 2022 7:00 am |
RNS |
Spread of breast cancer accelerates during sleep |
| 23rd Jun 2022 6:24 pm |
RNS |
Issue of Equity |
| 22nd Jun 2022 7:00 am |
RNS |
Secured contract from pharma services customer |
| 16th Jun 2022 7:00 am |
RNS |
Predicting immunotherapy response in SCLC |
| 14th Jun 2022 7:00 am |
RNS |
Potential role of invasive cellular protrusions |
| 30th May 2022 7:00 am |
RNS |
Partnership with major United States urology group |
| 27th May 2022 7:00 am |
RNS |
Molecular characterisation of CTCs |
| 25th May 2022 4:35 pm |
RNS |
Price Monitoring Extension |
| 25th May 2022 12:30 pm |
RNS |
ANGLE receives FDA clearance for Parsortix |
| 20th May 2022 7:00 am |
RNS |
Prostate Cancer UK funds new study using Parsortix |
| 28th Apr 2022 7:00 am |
RNS |
Preliminary Results |
| 20th Apr 2022 7:00 am |
RNS |
Notice of Preliminary Results and Webcast |
| 14th Apr 2022 7:00 am |
RNS |
Poster on Parsortix system presented at AACR 2022 |
| 1st Apr 2022 7:00 am |
RNS |
Identifying drug targets in cancer metastasis |
| 29th Mar 2022 7:00 am |
RNS |
Rapid information on patient response to therapies |
| 25th Mar 2022 7:00 am |
RNS |
Identifying therapeutic targets in TNBC patients |
| 15th Mar 2022 7:00 am |
RNS |
Update on laboratory accreditation |
| 9th Mar 2022 4:41 pm |
RNS |
Second Price Monitoring Extn |
| 9th Mar 2022 4:36 pm |
RNS |
Price Monitoring Extension |
| 2nd Mar 2022 6:29 pm |
RNS |
Holding(s) in Company |
| 18th Feb 2022 5:13 pm |
RNS |
Issue of Equity |
| 21st Jan 2022 7:00 am |
RNS |
Potential in immunotherapy treatment selection |
| 17th Jan 2022 7:00 am |
RNS |
Concordance of Parsortix with tissue biopsy |
| 13th Jan 2022 7:00 am |
RNS |
Update on lab accreditation and ovarian study |
| 10th Jan 2022 7:00 am |
RNS |
Insight into drug resistance in NSCLC |
| 22nd Dec 2021 6:29 pm |
RNS |
Issue of Equity |
| 1st Dec 2021 6:11 pm |
RNS |
Issue of Equity |
| 1st Dec 2021 7:00 am |
RNS |
Parsortix in RNA analysis of CTCs as tool in NSCLC |
| 26th Nov 2021 5:33 pm |
RNS |
Issue of Equity |
| 17th Nov 2021 10:32 am |
RNS |
Issue of Equity |
| 15th Nov 2021 7:00 am |
RNS |
Issue of LTIP Options and Share Options |
| 15th Nov 2021 7:00 am |
RNS |
Appointment of Chief Medical Officer |
